سعر جاوتيفيد 40مجم 30 قرص 2024

Febuxostat 40 mg film-coated tablets (Global Napi Pharmaceuticals), 3 strips x 10 tablets per pack.

• Chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable; not recommended for asymptomatic hyperuricemia.Population: AdultsGlobal Napi Pharmaceuticals (Egyptian manufacturer)
• Treatment of chronic hyperuricaemia in conditions where urate deposition has already occurred (including a history, or presence of, tophus and/or gouty arthritis) in adults.Population: AdultsEuropean Medicines Agency (EMA)
• Chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable; not recommended for asymptomatic hyperuricemia.Population: AdultsDailyMed (U.S. National Library of Medicine)

• EU: common adverse reactions include gout flares, liver function abnormalities, diarrhoea, nausea, headache, dizziness, rash and oedema.General active-ingredient information · European Medicines Agency (EMA)
• US: adverse reactions in ≥1% of patients and more than placebo were liver function abnormalities, nausea, arthralgia and rash.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• EU: hypersensitivity to febuxostat or to any of the excipients.General active-ingredient information · European Medicines Agency (EMA)
• US: contraindicated in patients being treated with azathioprine or mercaptopurine.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• EU: in patients with pre-existing major cardiovascular disease (e.g. myocardial infarction, stroke, unstable angina) more fatal cardiovascular events were seen with febuxostat than allopurinol in CARES, while FAST showed non-inferiority; treat such patients cautiously and monitor regularly.General active-ingredient information · European Medicines Agency (EMA)
• US boxed warning: gout patients with established cardiovascular disease treated with ULORIC had a higher rate of cardiovascular death than those treated with allopurinol; reserve for patients with inadequate response to, or intolerance of, allopurinol, or for whom allopurinol is not advisable.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• EU: serious hypersensitivity reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, anaphylaxis and DRESS have been reported, mostly in the first month; stop immediately and never restart in patients who developed such reactions.General active-ingredient information · European Medicines Agency (EMA)

• Mercaptopurine / azathioprineEU: concomitant use is not recommended (increased mercaptopurine/azathioprine levels and myelotoxicity); if unavoidable, reduce their dose to 20% or less of the previous dose and monitor closely.European Medicines Agency (EMA)
• Azathioprine / mercaptopurineUS: ULORIC is contraindicated in patients treated with azathioprine or mercaptopurine (increased exposure to 6-mercaptopurine may cause severe toxicity).DailyMed (U.S. National Library of Medicine)
• TheophyllineEU: febuxostat 80 mg with theophylline showed no pharmacokinetic interaction; no data for febuxostat 120 mg.European Medicines Agency (EMA)

• EU: very limited data in pregnancy; potential risk for humans unknown; febuxostat should not be used during pregnancy.General active-ingredient information · European Medicines Agency (EMA)
• US: limited available human data are insufficient to inform drug-associated risk; no adverse developmental effects in animal studies at exposures about 40-51 times the maximum recommended human dose.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• EU: not known whether febuxostat is excreted in human milk (excreted in rat milk); should not be used while breastfeeding.General active-ingredient information · European Medicines Agency (EMA)

English text not available for this section.